VivoSeq
Oncology

Metastatic Pancreatic Ductal Adenocarcinoma

11

Pipeline Programs↗

2

Active Trials↗

10

Companies Involved↗

Metastatic Pancreatic Ductal Adenocarcinoma is an emerging landscape with 11 programs across 10 companies. The most active players are Sanofi, Azurity Pharmaceuticals, Arcus Biosciences. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

0/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1A

Azurity Pharmaceuticals

1 program

Phase 1Arcus Biosciences logo

Arcus Biosciences

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

11 of 12 classified programs — the dominant modality here.

8%ALL OTHERSCell therapy18%

Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 92% of 13 pipeline programs.

Analysis

Trial Status

3

clinical trials

Recruiting1 · 33%
Terminated1 · 33%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination With FOLFOX Compared to Standard of Care in Subjects With First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288
Recruiting·AbbVie logoAbbVie·Preclinical·NCT07490301·900 enrolled
Phase I Study of Autologous Transgenic T-Cells Expressing High Affinity Mesothelin-Specific T-Cell Receptor (TCR) (FH-TCR Tᴍsʟɴ) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT04809766·9 enrolled
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma
Active, not recruiting·Arcus Biosciences logoArcus Biosciences·Phase 3·NCT06608927·610 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)